Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 01 Feb 2018
At a glance
- Drugs Pertuzumab (Primary) ; Paclitaxel; Trastuzumab
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 30 Jan 2018 Planned End Date changed from 1 Jan 2018 to 1 Jan 2019.
- 30 Jan 2018 Planned primary completion date changed from 1 Jan 2018 to 1 Jan 2019.
- 10 Jun 2017 Biomarkers information updated
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History